Adjuvant therapy with camrelizumab significantly improved 3-year event-free survival in patients with locoregionally advanced nasopharyngeal carcinoma compared with observation, according to findings ...

Please provide your email address to receive an email when new articles are posted on . Patients with nasopharyngeal cancer who received morning radiotherapy survived longer than those treated later ...

In patients with nasopharyngeal carcinoma who received induction-concurrent (chemo)radiotherapy, persistent Epstein-Barr virus (EBV) DNA positivity or its resurgence during treatment was associated ...

NPC is a disease that develops in a concealed area behind the nose and frequently presents with non-specific early signs, and in Malaysia, it is one of the most common cancers affecting men, with ...

Nasopharyngeal carcinoma (NPC), a malignancy that develops in the upper section of the throat behind the nose, occurs in fewer than one person out of 100,000 worldwide each year. Locally advanced ...

(RTTNews) - Biopharmaceutical company Akeso Inc. (AKESF) said in a statement that its Penpulimab has been approved for the first-line treatment of recurrent or metastatic nasopharyngeal cancer or NPC, ...

As a first-line therapy, the risk of disease progression or death was reduced by 55% in the pempulimab-kcqx group vs the placebo group. The Food and Drug Administration (FDA) has approved ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA® (tislelizumab), in combination with ...

Penpulimab-kcqx is approved for first-line treatment of recurrent or metastatic non-keratinizing NPC in combination with cisplatin or carboplatin and gemcitabine. As a single agent, penpulimab-kcqx is ...

Loqtorzi combined with chemotherapy nearly doubled median overall survival in nasopharyngeal carcinoma patients compared to chemotherapy alone, with a median survival of 64.8 months. The combination ...